An interventional study of iTBS in Schizophrenia; Psychosis, sponsored by Indrit Begue. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-19.
Sponsored by Indrit Begue · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Schizophrenia with a site in Switzerland — 6 open to participants now, 6 under way, 1 of them phase 3. Schizophrenia · Switzerland.
Among the 30 studies in Schizophrenia with a site in Switzerland, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 17 with no phase, and was the 28th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →6 of the 30 studies in Schizophrenia with a site in Switzerland are open now. Recruiting first, the newest first:
Psychiatric University Hospital, Zurich · Sites in Switzerland
Ages 18–65
Mclean Hospital · Sites in Switzerland, United States
Ages 18–35
Psychiatric University Hospital, Zurich · Sites in Switzerland
Ages 18–65
Psychiatric University Hospital, Zurich · Sites in Switzerland
Ages 18–65
Christina Andreou · Sites in Switzerland, Germany
Ages 18–40
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 27 interventional studies, 100 across the 3 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 30 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Indrit Begue as lead sponsor.
Indrit Begue has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies in Schizophrenia with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT05911529Psychiatric University Hospital, ZurichTracking the Linguistic Signatures of Motivational Interviewing in Acute Psychosis | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Schizophrenia with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is a double blind randomized clinical trials that examines the efficacy of cerebellar non invasive stimulation for apathy improvement in patients with schizophrenia
This double-blind RCT aims to explore the efficacy of intensiveTranscranial Magnetic Stimulation (TMS) in schizophrenia spectrum disorders. Previous studies in various disorders suggest that intensive TMS is efficacious and safe.
Participants will undergo neuronavigated intermittent theta burst TMS, targeted to individual network targets, at an accelerated protocol (multiple sessions a day), The primary goal is to determine the efficacy of this protocol in alleviating negative symptoms of schizophrenia.
Additionally, the study will measure the impact of accelerated TMS on a range of clinical and cognitive outcomes, along with neuroimaging markers indicative of symptom response.
Inclusion Criteria:
Inclusion criteria
Specific exclusion criteria related to psychopathology
Exclusion criteria related to MRI or TMS
Any implants controlled by physiological signs in/near the head
Other exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active intermittent theta burst stimulation (iTBS) to the cerebellum at 80% of active motor threshold.
Device: iTBS
Sham intermittent theta burst stimulation (iTBS) to the cerebellum
Device: iTBS
Intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses for up to 8 sessions daily for 5 days
Brief Negative Symptoms Scale - apathy subscale (BNSS-Apathy) at follow-up (FU) at T3. The primary endpoint will be assessed at baseline and all follow-up visits at week 1, 6 and 12.
This outcome measure focuses on the evaluation of changes in apathy symptoms in participants, utilizing the apathy subscale of the Brief Negative Symptoms Scale (BNSS-Apathy). Apathy symptoms will be assessed at baseline (pre-intervention) and subsequently at follow-up visits scheduled at weeks 1, 6, and 12 post-intervention. The primary endpoint of this measure is the change in BNSS-Apathy scores from baseline to each follow-up point, aiming to capture the trajectory of symptom changes across the study period. The BNSS-Apathy subscale score, derived from specific item responses, provides a quantitative measure of apathy severity, allowing for statistical analysis of symptom changes over time. Higher scores reflect greater severity of symptoms. Maximum score of BNSS-Apathy subscale score is 42 (severe apathy), minimum score is 0.
Time frame: at 12 weeks
Positive and Negative Symptoms Scale (PANSS) positive and negative subscores at follow-up
This outcome measure focuses on the evaluation of apathy and psychosis symptoms
Time frame: at 1 week
Positive and Negative Symptoms Scale (PANSS) positive and negative subscores at follow-up
This outcome measure focuses on the evaluation of apathy and psychosis symptoms
Time frame: at 6 weeks
Positive and Negative Symptoms Scale (PANSS) positive and negative subscores at follow-up
This outcome measure focuses on the evaluation of apathy and psychosis symptoms
Time frame: at 12 weeks
Self reported Negative Scale SNS scores and its sub-scales at follow-up
This outcome measure focuses on the self-reported evaluation of apathy
Time frame: at 1 week
Self reported Negative Scale SNS scores and its sub-scales at follow-up
This outcome measure focuses on the self-reported evaluation of apathy
Time frame: at 6 weeks
Self reported Negative Scale SNS scores and its sub-scales at follow-up
This outcome measure focuses on the self-reported evaluation of apathy
Time frame: at 12 weeks
Brief neurocognitive assessment (BNA) scores at follow-up
This outcome measure focuses on the evaluation of cognitive function
Time frame: at 6 weeks
Auditory Hallucinations Rating Scale (AHRS) scores at follow-up
This outcome measure focuses on the evaluation of auditory hallucinations
Time frame: at 6 weeks
Calgary Depression Scale (CDSS) scores at follow-up
This outcome measure focuses on the evaluation of depression symptoms
Time frame: at 6 weeks
Young Mania Rating Scale (YMRS) scores at follow-up
This outcome measure focuses on the evaluation of mania symptoms
Time frame: at 6 weeks
Personal and social performance scale (PSP) scores at follow-up
This outcome measure focuses on the evaluation of psychosocial functioning
Time frame: at 12 weeks
Deep-phenotyping outcome - sEBR (spontaneous eye blink)
This outcome measure focuses on the evaluation of sEBR
Time frame: at 6 weeks
Deep-phenotyping outcome - facial expressions
This outcome measure focuses on the evaluation of facial expressions
Time frame: at 6 weeks
Deep-phenotyping outcome - accelerometer
This outcome measure focuses on the evaluation of accelerometry
Time frame: at 6 weeks
Cerebellar-cortical functional connectivity
This outcome measure focuses on cerebellar-cortical functional connectivity
Time frame: at 1 week
Cerebellar-cortical structural connectivity
This outcome measure focuses on cerebellar-cortical structural connectivity
Time frame: at 6 weeks
Cerebellar-cortical structural connectivity
This outcome measure focuses on cerebellar-cortical structural connectivity
Time frame: at 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Sep 2026, 29 months after the start.
Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 29 months is below that.
Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.